Next Article in Journal
[Pt(O,O′-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells
Previous Article in Journal
Calixarenes: Generalities and Their Role in Improving the Solubility, Biocompatibility, Stability, Bioavailability, Detection, and Transport of Biomolecules
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 9
Issue 3
10.3390/biom9030091
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89

by
Chuangyan Zhai
1,2,
Shanzhen He
3,
Yunjie Ye
3,
Christine Rangger
2,
Piriya Kaeopookum
2,
Dominik Summer
2,
Hubertus Haas
4,
Leopold Kremser
5,
Herbert Lindner
5,
Julie Foster
6,
Jane Sosabowski
6 and
Clemens Decristoforo
2,*
1
School of Forensic Medicine, Southern Medical University, 510515 Guangzhou, China
2
Department of Nuclear Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
3
Department of Nuclear Medicine, Guangdong Academy of Medical Sciences, 510080 Guangzhou, China
4
Division of Molecular Biology, Biocenter, Medical University Innsbruck, 6020 Innsbruck, Austria
5
Division of Clinical Biochemistry, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria
6
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, E1 4NS London, UK
*
Author to whom correspondence should be addressed.
Biomolecules 2019, 9(3), 91; https://0-doi-org.brum.beds.ac.uk/10.3390/biom9030091
Submission received: 23 November 2018 / Revised: 4 February 2019 / Accepted: 25 February 2019 / Published: 6 March 2019
Browse Figures
Review Reports Versions Notes

Abstract

:
Fusarinine C (FSC) has recently been shown to be a promising and novel chelator for 89Zr. Here, FSC has been further derivatized to optimize the complexation properties of FSC-based chelators for 89Zr-labeling by introducing additional carboxylic groups. These were expected to improve the stability of 89Zr-complexes by saturating the 8-coordination sphere of [89Zr] Zr4+, and also to introduce functionalities suitable for conjugation to targeting vectors such as monoclonal antibodies. For proof of concept, succinic acid derivatization at the amine groups of FSC was carried out, resulting in FSC(succ)2 and FSC(succ)3. FSC(succ)2 was further derivatized to FSC(succ)2 AA by reacting with acetic anhydride (AA). The Zr4+ complexation properties of these chelators were studied by reacting with ZrCl4. Partition coefficient, protein binding, serum stability, acid dissociation, and transchelation studies of 89Zr-complexes were carried out in vitro and the results were compared with those for 89Zr-desferrioxamine B ([89Zr]Zr-DFO) and 89Zr-triacetylfusarinine C ([89Zr]Zr-TAFC). The in vivo properties of [89Zr]Zr-FSC(succ)3 were further compared with [89Zr]Zr-TAFC in BALB/c mice using micro-positron emission tomography/computer tomography (microPET/CT) imaging. Fusarinine C (succ)2AA and FSC(succ)3 were synthesized with satisfactory yields. Complexation with ZrCl4 was achieved using a simple strategy resulting in high-purity Zr-FSC(succ)2AA and Zr-FSC(succ)3 with 1:1 stoichiometry. Distribution coefficients of 89Zr-complexes revealed increased hydrophilic character compared to [89Zr]Zr-TAFC. All radioligands showed high stability in phosphate buffered saline (PBS) and human serum and low protein-bound activity over a period of seven days. Acid dissociation and transchelation studies exhibited a range of in vitro stabilities following the order: [89Zr]Zr-FSC(succ)3 > [89Zr]Zr-TAFC > [89Zr]Zr-FSC(succ)2AA >> [89Zr]Zr-DFO. Biodistribution studies of [89Zr]Zr-FSC(succ)3 revealed a slower excretion pattern compared to [89Zr]Zr-TAFC. In conclusion, [89Zr]Zr-FSC(succ)3 showed the best stability and inertness. The promising results obtained with [89Zr]Zr-FSC(succ)2AA highlight the potential of FSC(succ)2 as a monovalent chelator for conjugation to targeted biomolecules, in particular, monoclonal antibodies.

1. Introduction

Immuno-positron emission tomography (PET) is of great value for the development of monoclonal antibodies (mAbs) as therapeutic targeting vectors, enabling tracking and quantification of radiolabeled mAbs at high resolution and sensitivity [1]. In recent years, Zirconium-89 (89Zr), in particular, has become the most commonly-studied positron-emitting radionuclide for immuno-PET imaging. The physical half-life of 78.4 h is a good match with the biological half-life of mAbs, thus increasing the utility of PET in the development of this class of compound, and its medium mean positron energy of 0.395 MeV allows high-resolution PET imaging [2]. Additionally, in contrast to iodine-124, another long-lived positron-emitter, which has a rapid release of radioiodine from the cell after internalization, 89Zr is a residualizing radiometal and facilitates the visualization of tumors [3]. As an osteophilic radionuclide, immuno-PET imaging with 89Zr requires stable coordination of the radionuclide with the chelator to minimize dissociation resulting in bone accumulation in vivo.
To date, desferrioxamine B (DFO), see Figure 1, has been the most widely used bifunctional chelating system for 89Zr-based radiopharmaceuticals. Although chelation with DFO results in complexes with acceptable stability in pre-clinical as well as some clinical studies, it is far from being optimal due to the partial release of [89Zr]Zr4+ from the chelating system [4]. The released [89Zr]Zr4+ has been reported to accumulate in bone, particularly at late time points (3–7 days), which results in a decrease in image contrast, as well as an increase in radiation dose, especially to bone marrow [5,6,7,8,9,10]. The instability of DFO is attributed to the linear structure (which allows easy access to challenging cations and natural chelators in vivo), as well as to the incomplete saturation of the 8-coordination sphere of Zr4+ [11]. The development of novel high-stability Zr4+-ligands to minimize the uptake of liberated Zr4+ in the bone and other non-targeted tissue is an interesting and important goal. While many investigators focus on the optimization of the conjugation moiety between DFO and the biomolecule, attempts to develop new chelators are increasing [12,13,14,15,16,17,18,19,20,21,22]. Several novel octadentate and oxygen-rich 89Zr-chelators have been reported showing improved in vitro stability. These novel chelators are designed to be acyclic or macrocyclic by the addition of another hydroxamate unit [12,13,17,19,21] or introduce new chelating groups such as hydroxypyridinone and pyrocatechol groups [14,15,16,20].
Recently, we reported that fusarinine C (FSC), which has a 36-membered ring structure and three bidentate hydroxamates to coordinate 89Zr, showed superior stability and kinetic inertness compared to DFO. In particular, the excellent targeting properties of FSC bioconjugates in PET-imaging studies showed FSC to be a highly promising alternative chelator for 89Zr [23,24,25]. However, since FSC is hexadentate rather than octadentate, we postulated that improvements could be expected by introducing additional coordinating groups to saturate the coordination sphere of [89Zr]Zr4+. Another potential drawback of FSC as a 89Zr-bifunctional chelator lies in it having three functionalities for derivatization, which, despite facilitating the employment of multivalent concepts for small molecules, are not suitable for conjugation to macromolecules, especially antibodies. Therefore, a further aim of this study was to design a FSC-based mono-functional 89Zr-chelator. As proof of concept, modifications via succinic acid derivatization resulting in FSC(succ)2 acetic anhydride (AA) and FSC(succ)3, see Figure 1, were developed. This straightforward modification introduces additional carboxylic acid groups known to coordinate with Zr, which additionally can be utilized for bioconjugation strategies. In this study, the in vitro stability and transchelation properties of these 89Zr-complexes were investigated and compared with [89Zr]Zr-DFO and 89Zr-triacetylfusarinine C ([89Zr]Zr-TAFC). The in vivo properties of [89Zr]Zr-FSC(succ)3 were further compared with [89Zr]Zr-TAFC in BALB/c mice.

2. Materials and Methods

All commercially available reagents were of reagent grade and used as supplied with no further purification. Desferrioxamine B was obtained from Genaxxon Bioscience GmbH (Ulm, Germany). Triacetylfusarinine C was prepared and purified as described previously [23]. [89Zr]Zr-oxalate was purchased from Perkin Elmer, Inc (Waltham, MA, US) with an activity concentration of 900–1000 MBq per milliliter.
Purification of compounds was performed via a preparative reversed-phase high-performance liquid chromatography system (preparative RP-HPLC) using a Gilson 322 HPLC pump, a Gilson ultraviolet (UV)/VIS-155 detector (Gilson International B.V., Limburg, Germany), and a Eurosil Bioselect Vertex Plus 300 × 8 mm 5 μm C18A 300 Å column (Knauer, Berlin, Germany) with a flow rate of 3.0 mL/min. The gradient was as follows: 0–1.0 min 10% acetonitrile (CH3CN), 1.0–18.0 min 10–40% CH3CN (gradient A).
Analytical RP-HPLC analysis was performed with an UltiMate 3000 RS HPLC pump, an UltiMate 3000 RS column compartment (column oven temperature was set at 25 °C), an UltiMate 3000 UV-Vis variable wavelength detector (Dionex, Gemering, Germany), and a Raytest radiometric detector (Raytest GmbH, Straubenhardt, Germany). A Vydac 218 TP5215, 150 × 3.0 mm column (SRD, Vienna, Austria), flow rate 1.0 mL/min, and UV-Vis detection at 220/410 nm were employed with the following CH3CN/H2O/0.1% trifluoroacetic acid (TFA) gradient: 0–0.5 min 0% CH3CN/0.1% TFA, 0.5–7.0 min, 0–55% CH3CN/0.1% TFA (gradient B).

2.1. Fusarinine C

Fusarinine C was produced as described previously [23]. Briefly, the Aspergillus fumigatus mutant strain ∆sidG was cultured in iron-free minimal medium with 1% glucose for 36 h at 37 °C and 200 rpm. Biomass was removed by filtration. The media-containing siderophore was collected and concentrated. Additional purification was performed via preparative RP-HPLC (gradient A, tR = 10.2 min) followed by concentration and lyophilization. Analytical RP-HPLC (gradient B): tR = 4.7 min.

2.2. Fusarinine C (succ)3

To FSC (50 mg, 69 µmol) dissolved in 1 mL dimethylformamide (DMF), 34.5 mg of succinic anhydride (5 eq, 0.34 mmol) was added and the pH was adjusted to 4.5 using N,N-diisopropylethylamine (DIPEA). After shaking for 0.5 h, FSC(succ)3 was directly isolated via preparative RP-HPLC (gradient A, tR = 12.1 min) and confirmed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The collected fractions were concentrated and lyophilized. FSC(succ)3: yield: 63 mg, (61 µmol), 88%; MALDI TOF-MS: [M + H]+ = 1028.2 [C45H66N6O21; exact mass: 1026.4 (calculated)]. Analytical RP-HPLC (gradient B): tR = 5.6 min.

2.3. Fusarinine C(succ)2

The general synthesis procedure of FSC(succ)2 was the same as that of FSC(succ)3 except that a 2 eq molar excess of succinic anhydride was used. FSC(succ)2 was isolated from the byproducts (FSC-succ and FSC(succ)3) via preparative RP-HPLC (gradient A, tR = 11.5 min). FSC(succ)2: yield: 28 mg, (30 µmol), 43%. MALDI TOF-MS: [M + H]+ = 928.2 [C41H62N6O18; exact mass: 926.4 (calculated)]. Analytical RP-HPLC (gradient B): tR = 5.4 min.

2.4. Fusarinine C(succ)2AA

To FSC(succ)2 (10 mg, 11 µmol) dissolved in 0.5 mL DMF, 1 mL of acetic anhydride (AA) was added. After shaking for 10 min, FSC(succ)2AA was quickly isolated via preparative RP-HPLC (gradient A, tR = 11.9 min) and confirmed by MALDI-TOF-MS. The collected fractions were concentrated and lyophilized. FSC(succ)2AA: yield: 9 mg, (9.3 µmol), 85%. MALDI TOF-MS: [M + H]+ = 970.1 [C43H64N6O19; exact mass: 968.4 (calculated)]. Analytical RP-HPLC (gradient B): tR = 5.6 min.

2.5. Zr-Fusarinine C(succ)2AA and Zr-Fusarinine C(succ)3.

ZrCl4 (121 mg) was dissolved in 1 mL 0.1 M hydrochloric acid solution resulting in a concentration of 0.52 M. After dissolving FSC(succ)2AA (5 mg, 5.2 µmol) or FSC(succ)3 (5 mg, 4.9 µmol) in 1 mL water, a 1.2 eq molar excess of ZrCl4 (11.9 µL and 11.3 µL, respectively) was added. The reaction solutions were shaken gently for 5 min, then loaded onto a pre-activated Sep-Pak C18 cartridge. After washing the cartridge with 10 mL water, Zr-FSC(succ)2AA and Zr-FSC(succ)3 were eluted with 1mL methanol. The eluate fractions were dried by evaporation under nitrogen and weighed. The identities of the products were confirmed by electrospray ionization mass spectrometry (ESI-MS). Zr-FSC(succ)2AA: yield: 3.6 mg, (3.4 µmol), 65%. ESI-MS: [M + H]+ = 1,055.3 [C43H60N6O19Zr, see Figure 2A; exact mass: 1054.3 (calculated)]. RP-HPLC (gradient B): tR = 5.4 min. Zr-FSC(succ)3: yield: 3.7 mg, (3.3 µmol), 67%. ESI-MS: [M + H]+ = 1113.3 [C45H62N6O21Zr, see Figure 2B; exact mass: 1112.3 (calculated)]. Analytical RP-HPLC (gradient B): tR = 5.3 min.

2.6. 89Zr-Labeling

Approximately 30 MBq (30 µL) of [89Zr]Zr-oxalate was mixed with 27 μL of sodium carbonate (Na2CO3, 1 M) and incubated for 3 min at room temperature (RT) [26]. Thereafter, 100 μL of 4-(2-hydroxyethyl)-1-piperazineëthanesulfonic acid (HEPES) buffer (0.5 M, pH 7.0) was added to the reaction vial. Either DFO (32.8 μg), TAFC (42.6 μg), FSC(succ)2AA (48.5 μg) or FSC(succ)3 (51.4 μg) was added to the reaction vial. The labeling mixture was allowed to react at RT with a pH between 6.8 and 7.2 for 90 min. The reaction progress was monitored via analytical RP-HPLC (gradient B): [89Zr]Zr-DFO: tR = 4.8 min, [89Zr]Zr-TAFC: tR = 5.9 min, [89Zr]Zr-FSC(succ)2AA: tR = 6.1 min, and [89Zr]Zr-FSC(succ)3: tR = 6.0 min.
For animal experiments, 60 µL of CaCl2 (0.5 M) was added to the radiolabeling solution and a precipitate of Ca-oxalate appeared. The solution was then passed through a 0.2-µm filter to remove Ca-oxalate which may cause kidney failure. Subsequently, the filtrate was diluted to an appropriate volume using saline for administration to the BALB/c mice.

2.7. In Vitro Characterization

2.7.1. Distribution Coefficient

A volume of 500 µL PBS including 0.5 MBq radioligand ([89Zr]Zr-FSC(succ)2AA or [89Zr]Zr-FSC(succ)3) was combined with 500 µL octanol. The mixture was vortexed for 15 min, and centrifuged for 2 min at 2000 rcf. Subsequently, 50 µL aliquots of the aqueous and the octanol layer were collected, measured in a 2480 Wizard2 Automatic Gamma Counter (Perkin Elmer, Vienna, Austria), and distribution coefficient (logD) values were calculated using Excel 2013 (n = 5) (Redmond, WA, USA).

2.7.2. Stability Assay

Determination of the stability of [89Zr]Zr-DFO, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 was carried out by incubating the radioligands in PBS, a 1000-fold molar excess of ethylenediaminetetraacetic acid (EDTA) solution (radioligand vs. EDTA: 25 µM vs. 25 mM) with different pH (pH 7, pH 6, and pH 4), as well as in human serum (the human serum was obtained from author C.D. with his consent at the Medical University Innsbruck within a routine blood withdrawal procedure) for seven days at 37 °C. At selected time points, PBS and EDTA samples were analyzed in triplicate directly via analytical RP-HPLC, while serum aliquots were mixed with 500 µL of CH3CN, vortexed, and centrifuged at 20,000 rcf for 2 min. Then, the precipitate was washed three times using CH3CN before analysis.

2.7.3. Transchelation Study

[89Zr]Zr-DFO (50 µL) was mixed with a 1000-fold molar excess of either FSC(succ)2AA or FSC(succ)3 and [89Zr]Zr-TAFC (or [89Zr]Zr-FSC(succ)2AA, [89Zr]Zr-FSC(succ)3) (50 µL each) was mixed with a 1000-fold molar excess of DFO and incubated for seven days at RT. At selected time points, aliquots of the solutions were analyzed in triplicate directly via analytical RP-HPLC. The transchelation was determined by the ratio of [89Zr]Zr-DFO and [89Zr]Zr-FSC derivatives.

2.7.4. Protein Binding Assay

The protein binding property was evaluated by incubating [89Zr]Zr-FSC(succ)2AA or [89Zr]Zr-FSC(succ)3 for seven days at 37 °C in fresh human serum. Subsequently, 30 µL of the solution was passed through a size exclusion spin column (MicroSpinG-50 column, GE Healthcare, Buckinghamshire, UK) via centrifugation at 2000 rcf for 2 min. Protein binding of the complexes in triplicate was determined by measuring the activity on the column (non-protein bound) and the activity in the eluate (protein bound) in the gamma counter.

2.7.5. Biodistribution Study

All animal experiments were conducted in compliance with the Austrian animal protection laws and with the approval of the Austrian Ministry of Science (BMWFW-66.011/0049-WF/II/3b/2014) or were approved by the Animal Welfare and Ethical Review Body at Queen Mary University of London, and the UK Home Office (Project Licence 70/7603).
For the evaluation of biodistribution, four female BALB/c mice (Charles River Laboratories, Sulzfeld, Germany) were intravenously injected with [89Zr]Zr-FSC(succ)3 (1.5 MBq/mouse, 4.8 µg precursor) or [89Zr]Zr-TAFC (1.5 MBq/mouse, 4 µg) into the tail vein and sacrificed by cervical dislocation at 6 h post injection (p.i.). Organs (spleen, pancreas, stomach, intestine, kidney, liver, heart, and lung), blood, muscle tissue, and bone were dissected, weighed and then measured in the gamma counter to calculate the percentage of injected dose per gram of tissue (% ID/g). Statistical analysis was performed using an independent two-population t-test (significance level p = 0.05) and Origin 6.1 software (Northampton, MA, USA).

2.7.6. Micro-Positron Emission Tomography/Computer Tomography Imaging

Micro-Positron Emission Tomography/computer tomography (MicroPET/CT) imaging studies were carried out using an Inveon microPET/CT scanner (Siemens Preclinical Solutions, Knoxville, TN, USA). Healthy female BALB/c mice were injected intravenously with 5 MBq of either [89Zr]Zr-FSC(succ)3 (16 µg, n = 1) or [89Zr]Zr-TAFC (13 µg, n = 1). MicroPET/CT images were acquired under general anesthesia (isoflurane/O2) for 20 min. Imaging data were recorded via static scans at 80 min and 24 h p.i. The microPET/CT scans were reconstructed and merged with OSEM3D-SPMAP (PET, matrix size 256 × 256) and Feldkamp (CT, Shepp Logan filter). For evaluation of bone uptake, image-based quantitation was carried out by selecting volumes of interest around each knee region and % ID/cm3 were calculated for both time points (VivoQuant image analysis software, Invicro LLC, Boston, MA, USA) and expressed as mean values of left and right knees to compare both compounds.

3. Results

3.1. Synthesis

The straightforward synthesis of FSC(succ)2AA and FSC(succ)3 is shown in Scheme 1. Fusarinine C was reacted with succinic anhydride at pH 4.5 resulting in FSC(succ)3 and FSC(succ)2 in satisfactory yields of 88 ± 4.0% and 43 ± 4.5%, respectively. The unreacted amine group of FSC(succ)2 was further derivatized with a molar excess of acetic anhydride resulting in the final compound FSC(succ)2AA. High-performance liquid chromatograms demonstrated the purity of compounds above 96%, see Supplementary Materials, Figures S1–S3. Zr-FSC(succ)2AA and Zr-FSC(succ)3 were produced by the complexation of precursors with a molar excess of ZrCl4 in 0.1 M HCl solution at pH 1 within 5 min. Reaction of excess of precursor with ZrCl4 (0.1 eq) showed a comparable reaction efficiency. ESI-MS demonstrated not only the metal-to-ligand ratio of 1:1 but also the high-purity of Zr-complexes by analyzing the distinctive isotopic ratios of zirconium, see Supplementary Materials, Figures S4–S6.

3.2. 89Zr-Labeling

The 89Zr-labeling procedure of DFO, TAFC, FSC(succ)2AA and FSC(succ)3 was as previously described [23]. Quantitative radiolabeling was achieved in HEPES buffer at RT between pH 6.8 to 7.2 within 90 min. Quality control was carried out by analytical RP-HPLC (instead of the instant thin-layer chromatography (ITLC) method for [89Zr]Zr-DFO and [89Zr]Zr-TAFC reported previously in which [89Zr]Zr-DFO and [89Zr]Zr-TAFC remain at the origin and free [89Zr]Zr4+ migrates with the solvent front). This change was due to the undesirable spread of [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 along the ITLC strips.

3.3. Ex Vitro Characterization

Fusarinine C(succ)2AA and FSC(succ)3 showed high solubility in water, which is comparable to TAFC but different from recently reported novel octadentate chelators which seem to have poor solubility [9]. The lower logD values of [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 (−3.3 ± 0.1 and −3.5 ± 0.4, respectively) indicate higher hydrophilic properties than [89Zr]Zr-DFO and [89Zr]Zr-TAFC (−3.0 ± 0.1 and −2.0 ± 0.0, respectively). All radioligands showed high stability in PBS and human serum over a period of seven days and no demetallation was observed. The low protein-bound activity (<10%) over the whole monitoring period further confirmed the stability of radioligands in human serum. The logD, protein binding and stability in human serum data for [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 are summarized in Table 1 and compared with previously reported data of [89Zr]Zr-DFO and [89Zr]Zr-TAFC [23].
Acid dissociation experiments and transchelation studies were performed to compare the relative kinetic inertness of [89Zr]Zr-DFO, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3. Data of dissoctiation experiments are summarized in Figure 3. Briefly, at pH 7, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 revealed excellent resistance to transchelation over seven days, in contrast to that for [89Zr]Zr-DFO where almost 60% transchelation occurred, see Figure 3A. At pH 6, [89Zr]Zr-FSC(succ)3 remained intact (97.8%), being more stable than [89Zr]Zr-TAFC (94.4%) and significantly higher than [89Zr]Zr-FSC(succ)2AA (76%), see Figure 3B. At pH 4, the difference in stability of [89Zr]Zr-FSC(succ)3 and [89Zr]Zr-TAFC was more pronounced (87.9 vs. 70.3% of intact complex, respectively, at day 7), see Figure 3C.
Transchelation experiments are shown in Figure 4 and were performed by incubating: (A) [89Zr]Zr-DFO in a 1000-fold molar excess of FSC(succ)2AA or FSC(succ)3, or (B) [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 incubated in a 1000-fold molar excess of DFO. The transchelation ratio of (A) 89Zr from [89Zr]Zr-DFO to FSC(succ)2AA and FSC(succ)3 or (B) from [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 to DFO was easily calculated due to the significant difference of the retention time of radioligands. Almost quantitative transchelation of 89Zr from [89Zr]Zr-DFO to FSC(succ)2AA or FSC(succ)3 was observed within 1 h. In contrast, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3 showed a stronger resistance to transchelation to DFO. After 7 days, [89Zr]Zr-FSC(succ)3 showed the highest kinetic inertness (62.1% of intact complex) compared with [89Zr]Zr-TAFC and [89Zr]Zr-FSC(succ)2AA (39.8% and 30.8% of intact complex, respectively).

3.4. Biodistribution Study and Micro-Positron Emission Tomography/Computer Tomography (microPET/CT) Imaging

Based on the above-mentioned results, [89Zr]Zr-FSC(succ)3 and [89Zr]Zr-TAFC were further compared in vivo. Biodistribution data of [89Zr]Zr-FSC(succ)3 and [89Zr]TAFC are presented in Figure 5. Both radioligands show rapid clearance from the body, mainly through the kidneys and a rather low uptake, especially, in bones. A relatively slower blood clearance for [89Zr]Zr-FSC(succ)3 than for [89Zr]Zr-TAFC was observed (0.11 ± 0.08 vs. 0.05 ± 0.01% ID/g). Correspondingly, activity in heart (0.28 ± 0.08% ID/g), lung (0.21 ± 0.04% ID/g), muscle (0.25 ± 0.07% ID/g), and bone (0.24 ± 0.04% ID/g) were also higher. The microPET/CT images of the BALB/c mouse at 80 min p.i. and 24 h p.i. injected with either [89Zr]Zr-FSC(succ)3 or [89Zr]Zr-TAFC further confirmed similar rapid pharmacokinetics, see Figure 6, three-dimensional images: Supplementary Materials, Figures S7–S10. The kidneys and bladder were the primarily visible structures, which is related to excretion and kidney retention. At 80 min p.i. [89Zr]Zr-FSC(succ)3 showed some gall bladder activity and some minor activity in the small bowel which disappeared in the late images. More importantly, no bone uptake was observed, confirming the high in vivo stability of both compounds. An image-based quantitative comparison of bone uptake in the knee of mice revealed an even lower uptake of [89Zr]Zr-FSC(succ)3 with 0.083 and 0.026% ID/cm3 and of [89Zr]Zr-TAFC with 0.040 and 0.016% ID/cm3 at 80 min and 24 h, respectively, underlining the high in vivo stability of both chelates.

4. Discussion

The high potential of FSC as a novel multivalent 89Zr-bifunctional chelator was demonstrated by our group recently [23]. However, the six coordinating oxygens of FSC do not coordinatively saturate the Zr4+. In addition, three of the functionalities of FSC may limit its application to the macromolecules, especially antibodies. On this basis, we were interested in designing novel chelators based on FSC by introducing two or three carboxylic functional groups, which were expected to, on one hand, improve the stability of complexation by saturating the coordination sphere of [89Zr]Zr4+ and, on the other hand, reduce the number of conjugation groups making them suitable for conjugation to mAbs.
As proof of concept, two or three succinic acid groups were introduced into the FSC skeleton and FSC(succ)2, FSC(succ)2AA and FSC(succ)3 were synthesized with satisfactory yields. In our previous report, we discovered that iron protection is required for coupling FSC with targeting vectors [23]. However, the present study revealed that FSC can couple active groups such as anhydride groups at acidic pH, which provides a simpler conjugation approach. Moreover, the successful synthesis of FSC(succ)2 and FSC(succ)2AA opens a way to apply it to mAbs. FSC(succ)2, which has only one free amine functionality left, possesses the potential to couple mAbs with an activated group resulting in a monomeric FSC(succ)2-mAb.
In this study, the rapid and quantitative complexing of FSC(succ)2AA and FSC(succ)3 with ZrCl4 was reported and confirmed by ESI-MS. In our previous papers, we reported simple quantitative binding of ZrCl4 with TAFC at acidic pH (1–5) within 5 min [23] and quantitative labeling of TAFC with 89Zr-oxalate using acetate buffer [27]. On the basis of these findings, we can anticipate that [89Zr]ZrCl4 may be a better choice for labeling FSC derivatives in acetate buffer at appropriate pH. The advantage of [89Zr]ZrCl4 over 89Zr-oxalate lies not only in the shorter labeling time but also in avoiding the use of highly concentrated oxalate solution which potentially can result in the production of solid calcium oxalate causing kidney damage. In contrast to HEPES buffer, which requires additional quality control before clinical application, acetate buffer is entirely pharmaceutically compatible. For better understanding the exact coordination structures as well as their influence on stability, the preparation of single crystals of Zr-TAFC, Zr-FSC(succ)2AA and Zr-FSC(succ)3 for X-ray Diffraction was explored using different strategies; however, this failed. Multivalent hydroxamates seem not to crystallize easily, and this may be the reason that Zr(Me-AHA)4 is the only successfully crystallized Zr-hydroxamate compound [11].
To assess the relative kinetic inertness of [89Zr]Zr-DFO, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3, acid dissociation experiments were performed under acidic conditions. At pH 4, [89Zr]Zr-FSC(succ)3 was the most kinetically inert compound to acid dissociation for seven days, with [89Zr]Zr-TAFC showing moderate stability, followed by [89Zr]Zr-FSC(succ)2AA, and [89Zr]Zr-DFO totally decomposing on day 3. Transchelation studies showed the same but more pronounced trend. [89Zr]Zr-DFO showed total transchelation within 1 h whereas other 89Zr-complexes only showed limited transchelation after seven days. The improved stability and kinetic inertness of [89Zr]Zr-FSC(succ)3, [89Zr]Zr-TAFC, and [89Zr]Zr-FSC(succ)2AA over [89Zr]Zr-DFO were attributed to the macrocyclic structure. The superior stability of [89Zr]Zr-FSC(succ)3 over [89Zr]Zr-TAFC and [89Zr]Zr-FSC(succ)2AA may be as a result of the higher coordination number and better coordination configuration. The lower stability of [89Zr]-Zr-FSC(succ)2AA compared to [89Zr]Zr-TAFC may be related to the loss of the symmetrical structure. However, the superior stability of [89Zr]Zr-FSC(succ)2AA over [89Zr]Zr-DFO highlights the potential of FSC(succ)2 as a monomeric chelator in the development of novel 89Zr-tracers.
A direct biodistribution comparison revealed a much slower blood clearance of [89Zr]Zr-FSC(succ)3 than [89Zr]Zr-TAFC, resulting in a higher uptake in all major organs. Notably, the bone activity of [89Zr]Zr-FSC(succ)3 was significantly higher than that of [89Zr]Zr-TAFC, possibly mainly reflecting the slower clearance rather than being actual bone uptake. Even though different time points were chosen for an imaging study, this was confirmed by images at 24 h p.i. showing both radioligands without visible bone uptake. [89Zr]Zr-FSC(succ)3 also showed some hepatobiliary excretion in microPET/CT images at the early time point of 80 min, which was not depicted at 24 h p.i. and in the 6 h p.i. biodistribution study. The overall difference in biodistribution may be attributed to the difference in the chelate-radiometal net charge and polarity. [89Zr]Zr-TAFC possesses a positive net charge while [89Zr]Zr-FSC(succ)3 shows an overall negative charge character, which may potentially influence the excretion patterns of radiotracers. However, the difference in clearance rates between [89Zr]Zr-FSC(succ)3 and [89Zr]Zr-TAFC should not be a concern in its final application. Upon conjugation to a targeting biomolecule, the pharmacokinetics of the [89Zr]Zr-FSC(succ)3 complex will be completely superseded by those of biomacromolecules. Higher kidney and lower liver uptake compared to [89Zr]Zr-TAFC indicates a renal excretion pathway, which is consistent with the higher hydrophilicity of [89Zr]Zr-FSC(succ)3.

5. Conclusions

In our study, three FSC derivatives were synthesized and labeled with zirconium-89. [89Zr]Zr-FSC(succ)2AA showed superiority over [89Zr]Zr-DFO in vitro. Furthermore, [89Zr]Zr-FSC(succ)3 revealed the best stability and inertness in comparison to [89Zr]Zr-DFO, [89Zr]Zr-TAFC and [89Zr]Zr-FSC(succ)2AA. The superiority of FSC(succ)3 was attributed to the higher coordination number and better coordination configuration. The successful synthesis of FSC(succ)2 and FSC(succ)2AA highlights the potential of FSC(succ)2 as a monovalent 89Zr-chelator for the conjugation to mAbs. Further studies of FSC(succ)2-conjugated mAbs, especially in vivo, in comparison with their DFO counterparts and potentially other novel Zr-chelators, are needed to show the true potential of this approach for Immuno-PET.

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/2218-273X/9/3/91/s1, Figure S1: HPLC chromatogram of purified FSC(succ)2, Figure S2: HPLC chromatogram of purified FSC(succ)2AA, Figure S3: HPLC chromatogram of purified FSC(succ)3, Figure S4: The ESI-MS of [natZr]FSC(succ)3, Figure S5: The ESI-MS of [natZr]FSC(succ)2AA, Figure S6: The calculated isotope pattern for C45H63N6O21Zr ([natZr]FSC(succ)3), Figure S7: 3D microPET/CT images of [89Zr]Zr-FSC(succ)3 in a mouse 80min p.i., Figure S8: 3D microPET/CT images of [89Zr]Zr-FSC(succ)3 in a mouse 24h p.i., Figure S9: 3D microPET/CT images of [89Zr]Zr-TAFC in a mouse 80min p.i., Figure S10 3D microPET/CT images of [89Zr]Zr-TAFC in a mouse 24h p.i.

Author Contributions

Conceptualization, C.D. and C.Z.; methodology, C.Z., S.H., Y.Y., P.K., D.S., L.K. and J.F.; software, C.Z and S.H.; validation, C.R. and Y.Y.; formal analysis, C.Z. and C.R.; investigation, C.D., C.Z., H.L. and J.S.; resources, C.D., H.H., H.L. and J.S.; data curation, C.D. and C.Z.; writing—original draft preparation, C.Z. and C.D.; writing—review and editing, C.R., and J.S.; visualization, J.F. and J.S.; supervision, C.D.; project administration, C.D.; funding acquisition, C.D., C.Z., H.H.

Funding

We acknowledge the financial support of the National Natural Science Foundation of China (NSFC) grant 81701738, Austrian Science Foundation (FWF) grants P 25899-B23, I 1346, and Natural Science Foundation of Guangdong Province (project No. 2017A030310526).

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. Van Dongen, G.A.; Visser, G.W.; Lub-de Hooge, M.N.; De Vries, E.G.; Perk, L.R. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 2007, 12, 1379–1389. [Google Scholar] [CrossRef] [PubMed]
  2. Fischer, G.; Seibold, U.; Schirrmacher, R.; Wangler, B.; Wangler, C. 89Zr, a radiometal nuclide with high potential for molecular imaging with PET: Chemistry, applications and remaining challenges. Molecules 2013, 18, 6469–6490. [Google Scholar] [CrossRef] [PubMed]
  3. Stillebroer, A.B.; Franssen, G.M.; Mulders, P.F.; Oyen, W.J.; van Dongen, G.A.; Laverman, P.; Oosterwijk, E.; Boerman, O.C. ImmunoPET imaging of renal cell carcinoma with 124I-and 89Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother. Radiopharm. 2013, 28, 510–515. [Google Scholar] [CrossRef] [PubMed]
  4. van de Watering, F.C.; Rijpkema, M.; Perk, L.; Brinkmann, U.; Oyen, W.J.; Boerman, O.C. Zirconium-89 labeled antibodies: A new tool for molecular imaging in cancer patients. BioMed Res. Int. 2014, 2014, 203601. [Google Scholar] [CrossRef] [PubMed]
  5. Chang, A.J.; DeSilva, R.; Jain, S.; Lears, K.; Rogers, B.; Lapi, S. 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals 2012, 5, 79–93. [Google Scholar] [CrossRef] [PubMed]
  6. Aerts, H.J.; Dubois, L.; Perk, L.; Vermaelen, P.; van Dongen, G.A.; Wouters, B.G.; Lambin, P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 2009, 50, 123–131. [Google Scholar] [CrossRef] [PubMed]
  7. Holland, J.P.; Divilov, V.; Bander, N.H.; Smith-Jones, P.M.; Larson, S.M.; Lewis, J.S. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med. 2010, 51, 1293–1300. [Google Scholar] [CrossRef] [PubMed]
  8. Zeglis, B.M.; Mohindra, P.; Weissmann, G.I.; Divilov, V.; Hilderbrand, S.A.; Weissleder, R.; Lewis, J.S. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand diels–Alder click chemistry. Bioconjug. Chem. 2011, 22, 2048–2059. [Google Scholar] [CrossRef] [PubMed]
  9. van Rij, C.M.; Sharkey, R.M.; Goldenberg, D.M.; Frielink, C.; Molkenboer, J.D.; Franssen, G.M.; van Weerden, W.M.; Oyen, W.J.G.; Boerman, O.C. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J. Nucl. Med. 2011, 52, 1601–1607. [Google Scholar] [CrossRef] [PubMed]
  10. Heskamp, S.; van Laarhoven, H.W.; Molkenboer-Kuenen, J.D.; Franssen, G.M.; Versleijen-Jonkers, Y.M.; Oyen, W.J.; van der Graaf, W.T.; Boerman, O.C. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J. Nucl. Med. 2010, 51, 1565–1572. [Google Scholar] [CrossRef] [PubMed]
  11. Guérard, F.; Lee, Y.-S.; Tripier, R.; Szajek, L.P.; Deschamps, J.R.; Brechbiel, M.W. Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: Progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem. Commun. 2013, 49, 1002–1004. [Google Scholar] [CrossRef] [PubMed]
  12. Patra, M.; Bauman, A.; Mari, C.; Fischer, C.A.; Blacque, O.; Häussinger, D.; Gasser, G.; Mindt, T.L. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes. Chem. Commun. 2014, 50, 11523–11525. [Google Scholar] [CrossRef] [PubMed]
  13. Guérard, F.; Lee, Y.S.; Brechbiel, M.W. Rational Design, Synthesis, and Evaluation of Tetrahydroxamic Acid Chelators for Stable Complexation of Zirconium (IV). Chem. A Eur. J. 2014, 20, 5584–5591. [Google Scholar] [CrossRef] [PubMed]
  14. Pandya, D.N.; Pailloux, S.; Tatum, D.; Magda, D.; Wadas, T.J. Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89. Chem. Commun. 2015, 51, 2301–2303. [Google Scholar] [CrossRef] [PubMed]
  15. Ma, M.T.; Meszaros, L.K.; Paterson, B.M.; Berry, D.J.; Cooper, M.S.; Ma, Y.; Hider, R.C.; Blower, P.J. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with 89Zr 4+: Comparison with desferrioxamine-B. Dalton Trans. 2015, 44, 4884–4900. [Google Scholar] [CrossRef] [PubMed]
  16. Deri, M.A.; Ponnala, S.; Zeglis, B.M.; Pohl, G.; Dannenberg, J.J.; Lewis, J.S.; Francesconi, L.C. An alternative chelator for 89Zr radiopharmaceuticals: Radiolabeling and evaluation of 3,4,3-(LI-1, 2-HOPO). J. Med. Chem. 2014, 57, 4849–4860. [Google Scholar] [CrossRef] [PubMed]
  17. Seibold, U.; Wangler, B.; Wangler, C. Rational Design, Development, and Stability Assessment of a Macrocyclic Four-Hydroxamate-Bearing Bifunctional Chelating Agent for 89Zr. ChemMedChem 2017, 12, 1555–1571. [Google Scholar] [CrossRef] [PubMed]
  18. Rousseau, J.; Zhang, Z.; Dias, G.M.; Zhang, C.; Colpo, N.; Benard, F.; Lin, K.S. Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of 89Zr-labeled antibodies. Bioorg. Med. Chem. Lett. 2017, 27, 708–712. [Google Scholar] [CrossRef] [PubMed]
  19. Boros, E.; Holland, J.P.; Kenton, N.; Rotile, N.; Caravan, P. Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging. Chempluschem 2016, 81, 274–281. [Google Scholar] [CrossRef] [PubMed]
  20. Buchwalder, C.; Rodriguez-Rodriguez, C.; Schaffer, P.; Karagiozov, S.K.; Saatchi, K.; Hafeli, U.O. A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of 89Zirconium for positron emission tomography (PET) imaging. Dalton Trans. 2017, 46, 9654–9663. [Google Scholar] [CrossRef] [PubMed]
  21. Adams, C.J.; Wilson, J.J.; Boros, E. Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development. Mol. Pharm. 2017, 14, 2831–2842. [Google Scholar] [CrossRef] [PubMed]
  22. Pandya, D.N.; Bhatt, N.; Yuan, H.; Day, C.S.; Ehrmann, B.M.; Wright, M.; Bierbach, U.; Wadas, T.J. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem. Sci. 2017, 8, 2309–2314. [Google Scholar] [CrossRef] [PubMed]
  23. Zhai, C.; Summer, D.; Rangger, C.; Franssen, G.; Laverman, P.; Haas, H.; Petrik, M.; Haubner, R.; Decristoforo, C. Novel bifunctional cyclic chelator for 89Zr labeling–radiolabeling and targeting properties of RGD conjugates. Mol. Pharm. 2015, 12, 2142–2150. [Google Scholar] [CrossRef] [PubMed]
  24. Summer, D.; Rangger, C.; Klingler, M.; Laverman, P.; Franssen, G.M.; Lechner, B.E.; Orasch, T.; Haas, H.; von Guggenberg, E.; Decristoforo, C. Exploiting the Concept of Multivalency with 68Ga- and 89Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression. Contrast Media Mol. Imaging 2018, 2018, 3171794. [Google Scholar] [CrossRef] [PubMed]
  25. Summer, D.; Garousi, J.; Oroujeni, M.; Mitran, B.; Andersson, K.G.; Vorobyeva, A.; Lofblom, J.; Orlova, A.; Tolmachev, V.; Decristoforo, C. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Mol. Pharm. 2018, 15, 175–185. [Google Scholar] [CrossRef] [PubMed]
  26. Vosjan, M.J.; Perk, L.R.; Visser, G.W.; Budde, M.; Jurek, P.; Kiefer, G.E.; van Dongen, G.A. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 2010, 5, 739–743. [Google Scholar] [CrossRef] [PubMed]
  27. Petrik, M.; Zhai, C.; Novy, Z.; Urbanek, L.; Haas, H.; Decristoforo, C. In vitro and in vivo comparison of selected Ga-68 and Zr-89 labelled siderophores. Mol. Imaging Biol. 2016, 18, 344–352. [Google Scholar] [CrossRef] [PubMed]
Biomolecules 09 00091 g001 550
Figure 1. Structures of desferrioxamine B (DFO), fusarinine C (FSC), triacetylfusarinine C (TAFC), FSC(succ)2, FSC(succ)2AA and FSC(succ)3.
Figure 1. Structures of desferrioxamine B (DFO), fusarinine C (FSC), triacetylfusarinine C (TAFC), FSC(succ)2, FSC(succ)2AA and FSC(succ)3.
Biomolecules 09 00091 g001
Biomolecules 09 00091 g002 550
Figure 2. Postulated coordination structures of Zr-FSC(succ)2AA (A) and Zr-FSC(succ)3 (B).
Figure 2. Postulated coordination structures of Zr-FSC(succ)2AA (A) and Zr-FSC(succ)3 (B).
Biomolecules 09 00091 g002
Biomolecules 09 00091 sch001 550
Scheme 1. Synthesis strategies of FSC(succ)3 and FSC(succ)2AA.
Scheme 1. Synthesis strategies of FSC(succ)3 and FSC(succ)2AA.
Biomolecules 09 00091 sch001
Biomolecules 09 00091 g003a 550Biomolecules 09 00091 g003b 550
Figure 3. Acid dissociation studies of [89Zr]Zr-DFO (─⬛─), [89Zr]Zr-TAFC (─●─), [89Zr]Zr-FSC(succ)2AA (─▲─) and [89Zr]Zr-FSC(succ)3 (─▼─) in a 1000-fold molar excess of EDTA solution at pH 7 (A), pH 6 (B), and pH 4 (C).
Figure 3. Acid dissociation studies of [89Zr]Zr-DFO (─⬛─), [89Zr]Zr-TAFC (─●─), [89Zr]Zr-FSC(succ)2AA (─▲─) and [89Zr]Zr-FSC(succ)3 (─▼─) in a 1000-fold molar excess of EDTA solution at pH 7 (A), pH 6 (B), and pH 4 (C).
Biomolecules 09 00091 g003aBiomolecules 09 00091 g003b
Biomolecules 09 00091 g004 550
Figure 4. Transchelation studies: Percent of intact [89Zr]Zr-DFO (─⬛─) incubated in a 1000-fold molar excess of FSC(succ)3 or FSC(succ)2AA, and [89Zr]Zr-TAFC (─●─), [89Zr]Zr-FSC(succ)2AA (─▲─) and [89Zr]Zr-FSC(succ)3 (─▼─) incubated in a 1000-fold excess of DFO.
Figure 4. Transchelation studies: Percent of intact [89Zr]Zr-DFO (─⬛─) incubated in a 1000-fold molar excess of FSC(succ)3 or FSC(succ)2AA, and [89Zr]Zr-TAFC (─●─), [89Zr]Zr-FSC(succ)2AA (─▲─) and [89Zr]Zr-FSC(succ)3 (─▼─) incubated in a 1000-fold excess of DFO.
Biomolecules 09 00091 g004
Biomolecules 09 00091 g005 550
Figure 5. Comparison of biodistribution data of [89Zr]Zr-FSC(succ)3 (4.8 µg, 1.5 MBq, n = 4) with [89Zr]Zr-TAFC (4 µg, 1.5 MBq, n = 4) at 6 h post infection (p.i.) in BALB/c mice. * indicates significant differences between the two compounds (p < 0.05).
Figure 5. Comparison of biodistribution data of [89Zr]Zr-FSC(succ)3 (4.8 µg, 1.5 MBq, n = 4) with [89Zr]Zr-TAFC (4 µg, 1.5 MBq, n = 4) at 6 h post infection (p.i.) in BALB/c mice. * indicates significant differences between the two compounds (p < 0.05).
Biomolecules 09 00091 g005
Biomolecules 09 00091 g006 550
Figure 6. Micro-positron emission tomography/computer tomography images at 80 min p.i. and 24 h p.i. of BALB/c mice injected with either [89Zr]Zr-FSC(succ)3 or [89Zr]Zr-TAFC. Red arrow indicator: kidneys; blue arrow indicator: bladder. The single focal accumulation in the image of [89Zr]Zr-FSC(succ)3 80 min p.i. is related to gall bladder activity, additionally some activity in small bowel appears, which disappears at 24 h p.i.
Figure 6. Micro-positron emission tomography/computer tomography images at 80 min p.i. and 24 h p.i. of BALB/c mice injected with either [89Zr]Zr-FSC(succ)3 or [89Zr]Zr-TAFC. Red arrow indicator: kidneys; blue arrow indicator: bladder. The single focal accumulation in the image of [89Zr]Zr-FSC(succ)3 80 min p.i. is related to gall bladder activity, additionally some activity in small bowel appears, which disappears at 24 h p.i.
Biomolecules 09 00091 g006
Table
Table 1. LogD, protein binding, and stability in human data for [89Zr]Zr-DFO, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3.
Table 1. LogD, protein binding, and stability in human data for [89Zr]Zr-DFO, [89Zr]Zr-TAFC, [89Zr]Zr-FSC(succ)2AA and [89Zr]Zr-FSC(succ)3.
89Zr-ComplexLog DIncubation Time (days)Protein Binding (%)Stability in Human Serum (%)
[89Zr]Zr-DFO−3.0 ± 0.178.7 ± 1.099.3
[89Zr]Zr-TAFC−2.0 ± 0.076.8 ± 0.599.5
[89Zr]Zr-FSC(succ)2AA−3.3 ± 0.175.9 ± 1.699.4
[89Zr]Zr-FSC(succ)3−3.5 ± 0.478.3 ± 3.599.5

Share and Cite

MDPI and ACS Style

Zhai, C.; He, S.; Ye, Y.; Rangger, C.; Kaeopookum, P.; Summer, D.; Haas, H.; Kremser, L.; Lindner, H.; Foster, J.; et al. Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89. Biomolecules 2019, 9, 91. https://0-doi-org.brum.beds.ac.uk/10.3390/biom9030091

AMA Style

Zhai C, He S, Ye Y, Rangger C, Kaeopookum P, Summer D, Haas H, Kremser L, Lindner H, Foster J, et al. Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89. Biomolecules. 2019; 9(3):91. https://0-doi-org.brum.beds.ac.uk/10.3390/biom9030091

Chicago/Turabian Style

Zhai, Chuangyan, Shanzhen He, Yunjie Ye, Christine Rangger, Piriya Kaeopookum, Dominik Summer, Hubertus Haas, Leopold Kremser, Herbert Lindner, Julie Foster, and et al. 2019. "Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89" Biomolecules 9, no. 3: 91. https://0-doi-org.brum.beds.ac.uk/10.3390/biom9030091

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop